“Delaying the Onset of Type 1 Diabetes with Teplizumab: A Narrative Review of Autoantibody Screening and Who Would Actually Be Treated” (2022) Journal of Clinical Diabetes and Obesity, 2(1), pp. 7–12. doi:10.5281/zenodo.22238844.